A pre-need primer

Get oriented to clinical trials, before you need them

Most people hear the word “trial” for the first time in a hard moment, when the bandwidth to learn a whole new vocabulary isn’t there. This page is the calmer version of that conversation: a short primer on how trials are organized, where to look for them, the types worth knowing about, and the natural decision points where the question is worth raising.

We don’t pull or rank trials ourselves. That’s a clinical decision and belongs with your team. We just lower the cost of getting oriented.

What does “Phase 1, 2, 3” mean?

The phase tells you what the trial is trying to learn: and what kind of trade-off you’re making by joining.

Looking for early signals of benefit at the dose Phase 1 chose. Bigger group (50–300). Common landing spot for recurrent brain tumors.

Why it matters for you
By Phase 2, the dose is set and the team is watching for whether the drug actually shrinks tumors or extends time without growth. This is where a lot of brain-tumor patients land.

There’s also “Early Phase 1” (very small, very early) and trial listings that combine phases (e.g., Phase 1/2). The same logic applies. Check what the trial says it’s testing.

How to read inclusion / exclusion criteria

Every trial listing has a long list of bullets. Reading them cold is rough; here’s the shape to look for.

Inclusion vs. exclusion isn't a hierarchy
Inclusion lists who CAN join. Exclusion lists who CAN'T. You need to clear every inclusion bullet AND avoid every exclusion bullet. One unmet inclusion item or one matched exclusion item is enough to disqualify.
Look for the 'wash-out' windows
Many trials require X weeks since your last surgery, radiation, or chemo. If you're freshly post-op, you might need to wait, that's not a 'no,' it's a 'not yet.'
Performance status is non-negotiable
Trials usually require a Karnofsky (KPS) of 60, 70, or 80+. This is your team's rating of how independent you are day-to-day. If you're below the cutoff, that trial is closed to you for now.
Most criteria have flexibility, ask
Lab values, prior-treatment counts, and timing windows are sometimes negotiable. The trial's research coordinator is the right person to ask, not the website.
Don't self-disqualify on molecular markers you don't know yet
A trial that says 'IDH-mutant only' isn't a match if you don't know your IDH status. Get the path report before ruling yourself in or out.

Where else to look for trials

Clinicaltrials.gov is the best-known registry but it’s incomplete, particularly for newly-opened and some industry-sponsored trials. The most thorough search combines several sources.

Government

NCI Clinical Trials Search

The National Cancer Institute's own search is usually better curated for oncology than CT.gov, with better biomarker filtering and patient-friendly eligibility summaries.

Patient advocacy

Musella Foundation's curated guide

The Musella Foundation maintains an extensively-curated brain-tumor trial guide at virtualtrials.org, often including newly-opened trials before they reach the registries.

Major centers

Brain-tumor centers' own trial offices

NCI-designated centers (MSK, UCSF, MD Anderson, Duke Tisch, Dana-Farber, Penn, Northwestern, etc.) list their open trials on their own sites, including investigator-initiated ones that aren't on the registries.

Cooperative groups

NRG Oncology brain-tumor research

NRG Oncology is the main NCI-supported US cooperative group for adult brain-tumor research (succeeded the historical RTOG brain program). The Brain Tumor Trials Collaborative (BTTC) and the Adult Brain Tumor Consortium (ABTC) are separate multi-center academic networks worth searching by name too.

Expanded access

Compassionate / expanded access

Some drugs not yet FDA-approved are available outside formal trials through expanded access (compassionate use). The Musella Foundation maintains an actively-curated brain-tumor-specific list of currently-accessible programs, usually the most actionable starting point. The FDA's Expanded Access program and the Reagan-Udall Foundation describe the broader regulatory pathway.

International

International registries

The EU Clinical Trials Register and the WHO ICTRP list trials in Europe and globally that may not appear on US registries. Worth checking if you're open to traveling.

Types of brain-tumor trials

Trials fall into recognizable buckets. Knowing which fits your situation makes the conversation with your oncologist faster.

By disease phase

Newly diagnosed vs. recurrent

Most brain-tumor trials require recurrent or progressive disease at enrollment. A smaller but meaningful set are for newly-diagnosed patients, usually testing a new combination added to standard therapy. Worth asking BEFORE starting standard treatment if you might want to enroll on a newly-diagnosed trial.

By target

Molecularly-targeted

Trials requiring a specific biomarker: IDH mutation (vorasidenib and combinations), BRAF V600E (dabrafenib/trametinib), EGFR amplification, CDKN2A/B loss, MGMT methylation. Your NGS report determines which ones you might be eligible for.

By approach

Immunotherapy trials

Vaccines (DC vaccines, peptide), CAR-T cells, bispecific antibodies, checkpoint-inhibitor combinations, oncolytic viruses. Most require recent tumor tissue (some require fresh tissue). Worth asking your surgical team about tissue banking at the time of resection.

By approach

Device & delivery trials

TTFields combinations, focused ultrasound for blood-brain-barrier opening, intratumoral delivery (catheters, infusion devices), Gamma Knife combinations. Growing categories at academic centers, often complement rather than replace standard treatments.

By design

Basket and umbrella trials

Basket trials enroll patients across tumor types based on a shared molecular target. Umbrella trials enroll within one tumor type but assign different arms based on molecular profile. Both broaden eligibility and are increasingly common.

No treatment

Imaging, biomarker, supportive care

Some trials don’t test a treatment. They evaluate imaging techniques, blood-based biomarkers, or supportive interventions (cognitive rehab, exercise, fatigue). Low-risk, often welcoming, and contribute to the field.

When in your journey to ask about trials

Trials often have eligibility windows that close once certain treatments start. Knowing the natural decision points keeps you from finding out about an option after it’s already off the table.

At diagnosis

Before starting standard treatment

Some newly-diagnosed trials require enrollment BEFORE surgery, radiation, or temozolomide. Once you’ve started Stupp protocol, you’re out of those windows. Worth asking your neuro-oncologist explicitly: “Are there any trials I’d be eligible for as a newly-diagnosed patient, and would joining one delay anything important?”

At the time of resection

Banking tissue for future trial eligibility

Many immunotherapy and personalized-vaccine trials require fresh-frozen tissue from a recent resection. Tissue banked at surgery can make you eligible for trials that wouldn’t otherwise be open to you years later. Ask the surgical team about tissue banking even if no trial is on the table today.

At any imaging change

New finding on MRI: is this the time?

A scan showing change or possible progression is when many patients first ask about trials. The conversation can include both the formal next-line treatment AND any trials open at the next step. Often there’s no rush, but it’s the natural decision point to revisit the question.

At recurrence / progression

The most common entry point

The majority of brain-tumor trials are for recurrent or progressive disease. If your team is recommending switching to a recurrent- disease regimen, ask whether a trial is a reasonable parallel option, and whether being on the trial would preclude later salvage therapies if it doesn’t work.

Between recurrences

Maintenance and surveillance trials

Even when you’re stable, there are biomarker, imaging, and supportive-care trials that don’t conflict with your current treatment. These keep you connected to the research ecosystem and contribute to the field while costing you very little.

What to bring to a screening visit

Trial screening visits move faster when you arrive prepared. Coordinators routinely need the same set of records: bringing them up front avoids the most common reason for a delayed eligibility decision.

Records, lists, and people to have ready

Bring physical or digital copies. Most centers accept records via patient portal, USB, or printed packet. The research coordinator will tell you their preference when you call to confirm.

Pathology report (with NGS if available)

The integrated diagnosis (tumor type, grade, IDH, MGMT, 1p/19q, etc.) is the first thing the coordinator looks for.

Recent imaging (disc/USB or via portal)

Usually the most recent two scans. The trial team often wants to read the images themselves, not just the report.

Operative reports from prior surgeries

Especially the most recent resection. Extent of resection and what was sampled affects eligibility.

Complete medication list

Include over-the-counter meds and supplements. Wash-out windows for certain drugs are common eligibility criteria.

Prior cancer treatment timeline

Dates of surgery, radiation, chemo cycles, immunotherapy. Trials often count time since specific therapies.

Performance status assessment

Most trials require KPS or ECOG above a threshold. Ask your oncologist's office for the current number before the visit.

Insurance information

Even when the trial covers the experimental treatment, routine care during the trial usually bills your insurance.

Your written list of questions

What's the time commitment? Travel? Randomization? Placebo? Back-up if you don't tolerate it? Bring them written down.

A care partner

Bring someone who can listen, take notes, and ask the questions you forget. Many trial centers welcome and expect this.

Your local oncologist's contact info

The trial team will often communicate with your local team about lab schedules, imaging, and side-effect management.

Travel and lodging support

Many brain-tumor trials are based at academic centers that aren’t local. Out-of-pocket cost shouldn’t be the reason you don’t pursue one. There are real (often free) resources for travel and lodging.

Free lodging

American Cancer Society Hope Lodge

Free lodging for patients (and a caregiver) traveling for cancer treatment. Locations near most NCI-designated centers. Reservations through ACS or 1-800-227-2345.

Lodging directory

Joe's House

National directory of patient lodging options near specific hospitals: Hope Lodge, hospital hospitality houses, and discounted hotel rates. Free to use.

Free flights

Mercy Medical Angels · Corporate Angel Network

Mercy Medical Angels arranges free ground and air transportation for patients traveling for treatment. Corporate Angel Network matches cancer patients with available seats on corporate jets, free.

Ask first

Ask the research coordinator

Industry-sponsored trials often have per-visit travel reimbursement built into the budget. Investigator-initiated trials may have foundation-funded travel stipends. Ask the coordinator before you book anything; they often know about resources tied specifically to your trial.

Case management

Patient Advocate Foundation

Patient Advocate Foundation provides case management and financial aid for trial-related costs (travel, lodging, prescriptions) for patients with serious illness. Free service.

Hospital social work

Your hospital social-work team

Most academic cancer centers have dedicated social workers and patient navigators who specialize in connecting patients to financial-assistance and travel resources. Ask for a referral when you're being screened for a trial; they often have local resources not listed anywhere else.

Once you have a list of trials, what next?

A handful of trials in the result list isn’t a treatment plan; it’s a starting point for a conversation. Three things tend to help.

Save the NCT numbers

Every trial has an NCT ID (e.g., NCT05000000). Note 3–5 you'd want to ask about, with one sentence each on why it caught your eye.

Bring them to your team

Your neuro-oncologist can flag eligibility issues you'd never spot from the listing, and may know coordinators at the trial sites.

Email the research coordinator

Each listing has a contact. A short note (your diagnosis, prior treatments, location) gets you a faster yes/no than reading I/E criteria alone.

This is an educational tool and is not medical advice, diagnosis, or treatment. AI analyses can be wrong. Please share results with your doctor.